Hong Kong · Delayed Price · Currency is HKD Sinopharm Group Statistics
Total Valuation
Sinopharm Group has a market cap or net worth of HKD 52.30 billion. The enterprise value is 155.14 billion.
| Market Cap | 52.30B |
| Enterprise Value | 155.14B |
Important Dates
The last earnings date was Friday, October 23, 2026.
| Earnings Date | Oct 23, 2026 |
| Ex-Dividend Date | Jun 23, 2026 |
Share Statistics
Sinopharm Group has 3.12 billion shares outstanding. The number of shares has increased by 0.14% in one year.
| Current Share Class | 1.34B |
| Shares Outstanding | 3.12B |
| Shares Change (YoY) | +0.14% |
| Shares Change (QoQ) | -80.40% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 27.79% |
| Float | 1.27B |
Valuation Ratios
The trailing PE ratio is 6.26 and the forward PE ratio is 6.00. Sinopharm Group's PEG ratio is 2.05.
| PE Ratio | 6.26 |
| Forward PE | 6.00 |
| PS Ratio | 0.08 |
| PB Ratio | 0.32 |
| P/TBV Ratio | 0.58 |
| P/FCF Ratio | 1.60 |
| P/OCF Ratio | 1.53 |
| PEG Ratio | 2.05 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.99, with an EV/FCF ratio of 4.75.
| EV / Earnings | 18.53 |
| EV / Sales | 0.23 |
| EV / EBITDA | 5.99 |
| EV / EBIT | 7.30 |
| EV / FCF | 4.75 |
Financial Position
The company has a current ratio of 1.41, with a Debt / Equity ratio of 0.53.
| Current Ratio | 1.41 |
| Quick Ratio | 1.11 |
| Debt / Equity | 0.53 |
| Debt / EBITDA | 3.52 |
| Debt / FCF | 2.64 |
| Interest Coverage | 8.62 |
Financial Efficiency
Return on equity (ROE) is 7.97% and return on invested capital (ROIC) is 6.88%.
| Return on Equity (ROE) | 7.97% |
| Return on Assets (ROA) | 2.56% |
| Return on Invested Capital (ROIC) | 6.88% |
| Return on Capital Employed (ROCE) | 11.36% |
| Weighted Average Cost of Capital (WACC) | 3.72% |
| Revenue Per Employee | 7.04M |
| Profits Per Employee | 88,275 |
| Employee Count | 90,447 |
| Asset Turnover | 1.38 |
| Inventory Turnover | 7.91 |
Taxes
In the past 12 months, Sinopharm Group has paid 4.57 billion in taxes.
| Income Tax | 4.57B |
| Effective Tax Rate | 26.53% |
Stock Price Statistics
The stock price has decreased by -16.38% in the last 52 weeks. The beta is 0.43, so Sinopharm Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.43 |
| 52-Week Price Change | -16.38% |
| 50-Day Moving Average | 15.56 |
| 200-Day Moving Average | 17.90 |
| Relative Strength Index (RSI) | 62.74 |
| Average Volume (20 Days) | 7,007,086 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sinopharm Group had revenue of HKD 668.32 billion and earned 8.38 billion in profits. Earnings per share was 2.68.
| Revenue | 668.32B |
| Gross Profit | 47.13B |
| Operating Income | 19.83B |
| Pretax Income | 17.21B |
| Net Income | 8.38B |
| EBITDA | 22.10B |
| EBIT | 19.83B |
| Earnings Per Share (EPS) | 2.68 |
Balance Sheet
The company has 44.26 billion in cash and 86.23 billion in debt, with a net cash position of -41.97 billion or -13.45 per share.
| Cash & Cash Equivalents | 44.26B |
| Total Debt | 86.23B |
| Net Cash | -41.97B |
| Net Cash Per Share | -13.45 |
| Equity (Book Value) | 162.92B |
| Book Value Per Share | 32.70 |
| Working Capital | 122.84B |
Cash Flow
In the last 12 months, operating cash flow was 34.25 billion and capital expenditures -1.60 billion, giving a free cash flow of 32.66 billion.
| Operating Cash Flow | 34.25B |
| Capital Expenditures | -1.60B |
| Depreciation & Amortization | 2.29B |
| Net Borrowing | -25.68B |
| Free Cash Flow | 32.66B |
| FCF Per Share | 10.47 |
Margins
Gross margin is 7.05%, with operating and profit margins of 2.97% and 1.25%.
| Gross Margin | 7.05% |
| Operating Margin | 2.97% |
| Pretax Margin | 2.58% |
| Profit Margin | 1.25% |
| EBITDA Margin | 3.31% |
| EBIT Margin | 2.97% |
| FCF Margin | 4.86% |
Dividends & Yields
This stock pays an annual dividend of 0.80, which amounts to a dividend yield of 4.80%.
| Dividend Per Share | 0.80 |
| Dividend Yield | 4.80% |
| Dividend Growth (YoY) | 6.90% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 27.87% |
| FCF Payout Ratio | 7.55% |
| Buyback Yield | -0.14% |
| Shareholder Yield | 4.65% |
| Earnings Yield | 15.98% |
| FCF Yield | 62.33% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Analyst Forecast
The average price target for Sinopharm Group is 20.12, which is 20.05% higher than the current price. The consensus rating is "Buy".
| Price Target | 20.12 |
| Price Target Difference | 20.05% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | 2.32% |
| EPS Growth Forecast (3Y) | 4.27% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Sinopharm Group has an Altman Z-Score of 2.18 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.18 |
| Piotroski F-Score | 5 |